viewMediPharm Labs

Canntab completes first delivery of five SKUs ordered by MediPharm Labs Corp

The total purchase order is about $1.3 million and Canntab intends to deliver the entire order by the end of 2020

MediPharm Labs - Canntab Therapeutics Limited completes its first delivery of five SKU's ordered by MediPharm Labs Corp
So far, two of the SKUs have been delivered to MediPharm Labs

Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1.F), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, has completed its first delivery of SKU's ordered by MediPharm Labs Corp (TSE:LABS) (OTCMKTS:MEDIF).

In a statement Tuesday, Canntab said the total purchase order is about $1.3 million and it intends to deliver the entire order by the end of 2020. So far, two of the five SKUs (stock-keeping unit) have been delivered.

READ: Canntab to launch in Australia and take part in the nation’s largest cannabis research study 

"Our first commercial production and delivery of this initial portion of our order from MediPharm Labs Corp is a major milestone event for our company for three important reasons,” said Canntab CEO Larry Latowsky.

“First, this is evidence our science, quality assurance programs and production can be executed with the required standards to reflect our unique patented product of pressed tablets and caplets. Second, Canntab's wide range of products will finally be available to all Canadians through a variety of retail and wholesale channels.”

He added: “Finally, Canntab will be able to recognize revenue from its core product that will have a strong distribution base which will result in continuous sales through further expansion. Canntab will continue to enhance shareholder value by growing revenue through its domestic channels and expanding sales to international customers."

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: MediPharm Labs

Price: - -

Market: TSX-V
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MediPharm Labs named herein, including the promotion by the Company of MediPharm Labs in any Content on the Site, the Company receives from...


MediPharm announces deal with Pharma giant STADA that will transform company...

MediPharm Labs Corp (TSE: LABS-OTCQX: MEDIF) CEO Pat McCutcheon joined Steve Darling from Proactive to share details about an exclusive supply agreement European Consumer Healthcare and Generics company, STADA. This deal will see MediPharm supply GMP certified medical cannabis products to...

on 10/06/2020

2 min read